ORC4 as A Potential Drug Target for Ovarian Cancer (G5000)

Target Name: ORC4

NCBI ID: G5000

ORC4

ORC4 as A Potential Drug Target for Ovarian Cancer

ORC4 (Ovarian cancer recurrence) is a protein that is expressed in high levels in ovarian cancer cells. ORC4 has been identified as a potential drug target (or biomarker) due to its over-expression in ovarian cancer and its involvement in the development of resistance to chemotherapy.

ORC4 is a transcription factor that plays a role in the regulation of gene expression in cancer cells. It is expressed in high levels in ovarian cancer cells and has been shown to be involved in the development and progression of ovarian cancer. ORC4 has been shown to promote the growth and survival of ovarian cancer cells, and it has been identified as a potential drug target due to its over-expression in ovarian cancer.

One of the key challenges in the treatment of ovarian cancer is the development of resistance to chemotherapy. Ovarian cancer cells can evolve to resist the effects of chemotherapy by acquiring new genetic mutations, such as the acquisition of the Her2/PR positive gene, which can lead to the development of Her2-positive ovarian cancer. ORC4 has been shown to contribute to the development of resistance to chemotherapy in ovarian cancer by promoting the expression of genes that are involved in cell survival and the acquisition of new genetic mutations.

In addition to its role in the development of resistance to chemotherapy, ORC4 has also been shown to be involved in the regulation of cell growth and differentiation. ORC4 has been shown to promote the expression of genes that are involved in cell growth and differentiation, such as the TGF-β gene. This suggests that ORC4 may play a role in the regulation of cell growth and differentiation in ovarian cancer.

ORC4 has also been shown to be involved in the regulation of the immune response. ORC4 has been shown to interact with the immune checkpoint protein PD-1, and the combination of PD-1 and ORC4 has been shown to enhance the effectiveness of PD-1 blockade in ovarian cancer.

Despite its potential as a drug target, ORC4 has not yet been shown to be a reliable biomarker for the diagnosis or prognosis of ovarian cancer. Further research is needed to determine the role of ORC4 in ovarian cancer and to develop new diagnostic or therapeutic approaches based on its potential as a drug target.

In conclusion, ORC4 is a protein that has been identified as a potential drug target (or biomarker) due to its over-expression in ovarian cancer and its involvement in the development of resistance to chemotherapy. Further research is needed to determine the role of ORC4 in ovarian cancer and to develop new diagnostic or therapeutic approaches based on its potential as a drug target.

Protein Name: Origin Recognition Complex Subunit 4

Functions: Component of the origin recognition complex (ORC) that binds origins of replication. DNA-binding is ATP-dependent. The specific DNA sequences that define origins of replication have not been identified yet. ORC is required to assemble the pre-replication complex necessary to initiate DNA replication. Binds histone H3 and H4 trimethylation marks H3K9me3, H3K27me3 and H4K20me3

The "ORC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ORC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets